Review of Pharmacology - 9E (2015)

Review of Pharmacology
Contd...
Ramucirumab VEGFR-2 Non-small cell Lung cancer and cancer of
gastroesophageal junction
Ranibizumab VEGF Neovascular Macular degeneration, Macular edema
following retinal vein occlusion
Rituximab CD 20 B-cell NHL
Rilonacept IL-1 CAPS
Secukinumab IL-17a Plaque psoriasis
Siltuximab IL-6 Castleman’s disease
Tocilizumab IL-6R SLE, RA
Trastuzumab her-2/neu Breast cancer, Stomach and gastro-esophageal
junction carcinoma
Ustekinumab IL-12, IL-23 Plaque psoriasis
Vedolizumab α 4
b 7
Ulcerative colitis
Crohn’s disease
Nomenclature of Monoclonal Antibodies
Immunomodulators
Name of the monoclonal antibody can be devided into four parts.
Prefix + Target subsystem + Origin subsystem + Suffix
• Suffix for all monoclonal antibodies is mab
• Depending on the source of origin, various names are given, e.g. u stands for human,
xi for chimeric etc.
• Target is identified by specific letters, e.g. vi for virus, ci for circulation .
• Previously, target consisted of three letters (first consonant, second vowel and third consonant)
but third consonant can be deleted for ease of pronounciation. In 2009, new and
shorter target subsystems were introduced.
• Prefix is different for each monoclonal antibody.
Prefix Target Subsystem Source Subsystem Suffix
Variable
Old New Meaning Meaning
vi (r) v (i) Viral u human
ba (c) b (a) Bacterial 0 mouse
li (m) l (i) lower immunity a rat
fu (ng) f (u) fungal i primate mab
ne (r) n (e) nervous system xi chimeric
ki (n) k (i) Interleukin as target zuaxo humanizedrat mouse hybrid
mu (l) - musculoskeletal xizu chimeric humanized hybrid
o (s) s (o) Bone
co (l)
me (l)
Colonic tumor
Melanoma
ma (r) - t(u) Mammary tumor
go (t)
go (v)
pr (o)
tu (m)
Testicular tumor
Ovarian tumor
Prostate tumor
Miscellaneous tumor
676
https://kat.cr/user/Blink99/